If you have symptoms of coronavirus (COVID-19) – a high temperature, a new continuous cough, or a loss of, or change in, your normal sense of smell or taste (anosmia) – the advice is to stay at home for seven days. All members of this household should remain at home for 14 days.

If you think you have symptoms, please do not attend your hospital appointment until you are advised it is safe to do so. Please contact us to rearrange your appointment, or to re-organise treatment and tests.

Live trials for COVID-19

COVID-19 clinical trials

We are carrying out a number of trials for patients who are being treated at or admitted to NUH for COVID-19.

Our aim is to offer every patient with suspected or confirmed COVID-19 the opportunity to take part in this vital research.

Our research is part of the national and international response to COVID-19. Our expert clinical research teams are helping to find the most effective treatments:

RECOVERY - there are no specific treatments for COVID-19. This trial is investigating five different drugs, currently used for other conditions, to see if they have benefits for patients with COVID-19. The Randomised Evaluation of COVid-19 thERapY (RECOVERY) trial will provide doctors and health services with information they need to determine which treatments should be used. Initially for adults, we have now extended this trial at NUH to include newborns, children and young people under the age of 18 years.

ISARIC - NUH is already part of the International Severe Acute Respiratory and Emerging Infection Consortium (ISARIC) which is working to investigate severe acute respiratory illnesses (SARI). Data from patients at NUH suspected of having, or who are confirmed with, COVID-19 is now being included in this research.


PRIEST – this study is investigating the most effective ways of triaging people with suspected respiratory infections in emergency care during a pandemic.


REMAP-CAP – this study is identifying the most clinically effective interventions for adult patients admitted to an intensive care unit with community-acquired pneumonia and COVID-19.


GenOMICC – looking into the genetic susceptibility of patients to COVID-19 in critical care. This trial is aiming to find genetic markers which may help researchers and clinicians to identify patients who are at greater risk.

UKOSS - the UK Obstentrics Surveillance System (UKOSS) is collecting data from pregnant women who have a COVID-19 diagnosis to help understand more about how the virus may affect women and infants.

SNG001 - this trial is investigating the use of a formulation of the drug, interferon beta, in adults with COVID-19. In this trial, patients will either receive the drug or a placebo (which does not contain any active drug). The drug will be given to patients using an inhaler.

RECOVERY-RS - this trial is investigating the most effective way to administer oxygen to COVID-19 patients. Methods including CPAP and High Flow Nasal Oxygen (HFNO) are being used, comparing with more commonly used masks and nasal tubes.

ACCORD-2 - this is a national trial to fast-track the development of new drugs for treating COVID-19. It is a partnership between the NHS, the pharmaceutical industry and specialist research centres including the NIHR Nottingham Clinical Research Facility based at NUH.